CompBioMed Conference – CompBioMed Conference 2023
Description: Developing novel treatments for neurodegeneration
therapy (9841) company (8810) treatment (2676) biotech (646) pharmaceuticals (629) neurology (386) drug development (112) therapeutics (77) cns (75) neurodegeneration (19)
Nevrargenics Ltd is a UK-based neuroscience company specialising in the discovery and development of novel medicines for the treatment of neurodegenerative disease, such as Alzheimer’s, Parkinson’s, Multiple Sclerosis, Amyotrophic Lateral Sclerosis and other neurological and psychiatric diseases.
Disruptive Technology Our platform technology approach to treating neurodegenerative diseases is based on small molecules that modulate Retinoid Acid Receptors, a type of Nuclear Receptors - regulating expression of many genes involved in adult brain and neural functions.
Our product portfolio includes multiple drug candidates. Our lead drug candidate NVG0645 is extraordinarily potent, highly penetrative to blood-brain barrier and potentially disease reversing in AD, PD, ALS & FTD models.
CompBioMed Conference – CompBioMed Conference 2023